Tamoxifen-induced gene expression is a method used in molecular biology and neuroscience to activate transcription of a specific gene by application of the drug tamoxifen. It is based on the expression of a mutated estrogen receptor (ERT2) fused to Cre recombinase. [1] In the absence of tamoxifen, the receptor is inactive and sequestered in the cytoplasm. When tamoxifen is administered, it binds to ERT2, causing the Cre-ERT2 fusion protein to move into the cell's nucleus, where it can perform its recombination function. The gene of interest, encoding e.g. the fluorescent protein GFP, contains a LoxP-flanked stop cassette that prevents expression unless it is excised by Cre recombinase. [2]
When used in mice, the Cre-ERT2 system allows for excellent temporal control: Administration of tamoxifen triggers genetic changes at a precise time point in development or adult life. However, depending on the type of target cell, the gene of interest may not be successfully activated in every cell, leading to mosaic expression.
The Cre-ERT2 system has been harnessed to express genes of interest, e.g. fluorescent markers or optogenetic tools, in highly active neurons. For this purpose, it is driven by the immediate early gene Fos. [3] [4] This approach, called Targeted Recombination in Active Populations (TRAP, TRAP2), is used to investigate learning and memory in mice on the cellular level. [5] [6] [7]